Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michiel W van der Linden

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
European Journal of Public Health|September 6, 2005
Prevalence estimates of asthma or COPD from a health interview survey and from general practitioner registration: what's the difference?Ashna D Mohangoo, Michiel W van der Linden, François G Schellevis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 11, 2009
Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004Michiel W van der Linden, Arian W Plat, Joelle A Erkens, et al.
Drug Safety|May 23, 2009
Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the NetherlandsMichiel W van der Linden, Fernie J A Penning-van Beest, Tamar Nijsten, et al.
Caries Research|June 15, 2023
Assessment of spin in the abstracts of randomized controlled trials in dental caries with statistically nonsignificant results for primary outcomes: A methodological studyNaichuan Su, Michiel W van der Linden, Clovis M Faggion, et al.
Pharmacoepidemiology and Drug Safety|October 27, 2007
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawalMyrthe P P Sukel, Michiel W van der Linden, Connie Chen, et al.
Current Medical Research and Opinion|June 27, 2008
LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life resultsEdith M Heintjes, Mark W Hirsch, Michiel W van der Linden, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2015
Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib AssessmentsSarah Kleijnen, Mohammed Fathallah, Michiel W van der Linden, et al.
International Journal of Medical Informatics|September 18, 2007
Development of a case-based system for grouping diagnoses in general practiceMarion C J Biermans, Dinny H de Bakker, Robert A Verheij, et al.
Current Medical Research and Opinion|February 13, 2009
Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The NetherlandsMichiel W Van der Linden, Sabine Gaugris, Ernst J Kuipers, et al.
International Dental Journal|July 14, 2026
From Barriers to Solutions: A Community Network Approach to Equitable Oral Healthcare AccessSehida Begovic, Michiel W van der Linden, Sterre J Gitz, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
European Journal of Public Health|September 6, 2005
Prevalence estimates of asthma or COPD from a health interview survey and from general practitioner registration: what's the difference?Ashna D Mohangoo, Michiel W van der Linden, François G Schellevis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 11, 2009
Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004Michiel W van der Linden, Arian W Plat, Joelle A Erkens, et al.
Drug Safety|May 23, 2009
Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the NetherlandsMichiel W van der Linden, Fernie J A Penning-van Beest, Tamar Nijsten, et al.
Caries Research|June 15, 2023
Assessment of spin in the abstracts of randomized controlled trials in dental caries with statistically nonsignificant results for primary outcomes: A methodological studyNaichuan Su, Michiel W van der Linden, Clovis M Faggion, et al.
Pharmacoepidemiology and Drug Safety|October 27, 2007
Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawalMyrthe P P Sukel, Michiel W van der Linden, Connie Chen, et al.
Current Medical Research and Opinion|June 27, 2008
LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life resultsEdith M Heintjes, Mark W Hirsch, Michiel W van der Linden, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2015
Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib AssessmentsSarah Kleijnen, Mohammed Fathallah, Michiel W van der Linden, et al.
International Journal of Medical Informatics|September 18, 2007
Development of a case-based system for grouping diagnoses in general practiceMarion C J Biermans, Dinny H de Bakker, Robert A Verheij, et al.
Current Medical Research and Opinion|February 13, 2009
Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The NetherlandsMichiel W Van der Linden, Sabine Gaugris, Ernst J Kuipers, et al.
International Dental Journal|July 14, 2026
From Barriers to Solutions: A Community Network Approach to Equitable Oral Healthcare AccessSehida Begovic, Michiel W van der Linden, Sterre J Gitz, et al.
Pageof 2